PD
PDRX.US Pd-Rx Pharmaceutical
- Market cap
- USD 5.75M
- P/E
- 2.9x
- P/B
- -
- ROE
- -2.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2025.
Is PDRX.US undervalued?
Graham numberThe Graham number of Pd-Rx Pharmaceutical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pd-Rx Pharmaceutical fundamental analysis
No fundamental analysis for Pd-Rx Pharmaceutical yet.
Pd-Rx Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pd-Rx Pharmaceutical
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a ha…
Full company profilePd-Rx Pharmaceutical financial statements
Pd-Rx Pharmaceutical annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 21.5M | 26.0M | 25.0M | 20.9M | 21.0M | 21.6M | 28.7M | 21.3M | 18.9M | 18.3M |
| Gross Profit | 7.57M | 7.84M | 8.54M | 7.58M | 6.26M | 6.96M | 11.1M | 6.71M | 5.62M | 5.43M |
| Operating Income | 763K | 974K | 891K | -65.7K | -238K | 876K | 4.00M | -190K | -952K | -477K |
| EBITDA | 970K | 1.18M | 1.16M | 163K | -39.5K | 1.95M | 4.13M | 12.3K | -560K | -328K |
| Net Income | 508K | 627K | 621K | -12.9K | -384K | 1.86M | 3.03M | -98.1K | -753K | -258K |
| EPS | 0.30 | 0.36 | 0.36 | -0.01 | -0.22 | 1.08 | 1.83 | -0.06 | -0.46 | -0.17 |
| Balance Sheet | ||||||||||
| Total Assets | 13.3M | 12.6M | 12.7M | 8.69M | 8.79M | 10.9M | 13.2M | 13.0M | 12.9M | 12.0M |
| Total Liabilities | 2.02M | 1.30M | 1.92M | 1.68M | 2.17M | 2.43M | 1.86M | 1.70M | 2.37M | 1.74M |
| Shareholders' Equity | 11.2M | 11.3M | 10.8M | 7.01M | 6.63M | 8.48M | 11.4M | 11.3M | 10.5M | 10.2M |
| Cash & Short-term Investments | 8.00M | 8.33M | 7.36M | 3.16M | 3.46M | 2.90M | 5.47M | 6.83M | 5.40M | 6.17M |
| Total Debt | - | - | - | - | 934K | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.86M | 956K | 422K | -284K | -587K | -466K | 3.24M | 1.79M | -1.35M | 765K |
| Capital Expenditure | 89.7K | 147K | 274K | 146K | 49.7K | 108K | 550K | 427K | 77.9K | 2.44K |
| Free Cash Flow | 1.77M | 809K | 148K | -430K | -636K | -574K | 2.69M | 1.36M | -1.43M | 763K |
| Ratios | ||||||||||
| ROE | 4.5% | 5.5% | 5.8% | -0.2% | -5.8% | 21.9% | 26.7% | -0.9% | -7.2% | -2.5% |
| ROA | 3.8% | 5.0% | 4.9% | -0.1% | -4.4% | 17.0% | 22.9% | -0.8% | -5.9% | -2.1% |
| Net Profit Margin | 2.4% | 2.4% | 2.5% | -0.1% | -1.8% | 8.6% | 10.6% | -0.5% | -4.0% | -1.4% |
| Debt to Equity | - | - | - | - | 0.14x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pd-Rx Pharmaceutical dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 13, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 3.77M | 2.20 | - |
| 2018 | USD 1.13M | 0.66 | 182.2% |
| 2017 | USD 516K | 0.30 | 82.3% |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Pd-Rx Pharmaceutical
Ownership data of Pd-Rx Pharmaceutical is not available yet.
Pd-Rx Pharmaceutical company profile
- Company name
- Pd-Rx Pharmaceutical
- Ticker
- PDRX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- June
- Address
- 727 North Ann Arbor, Oklahoma City, OK, United States, 73127
- Phone
- 800 299 7379
- Website
- pdrx.com
About Pd-Rx Pharmaceutical
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a handling package; and PD-Rx Net, a web-based application designed to track prescriptions filled at the point of care and print prescription labels for prescriptions that are filled onsite. Further, it provides primary care, urgent care, pain management, occupational and orthopedic medicine, bariatric, dental, and other physician dispensing services. The company serves the governmental, commercial, and point-of-care pharmaceutical industry. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is based in Oklahoma City, Oklahoma.
Pd-Rx Pharmaceutical management
4- Dr. Robert D. Holsey D.O., R.Ph.Chairman, CEO & President · born 1953
- Mr. Robert L. Baker CPACFO, Treasurer & Director · born 1949
- Mr. Jack L. McCall IICOO, Executive VP of Marketing & Sales, Secretary and Director · born 1960
- Mr. Robert L. SurovecRegulatory Affairs Compliance Officer · born 1949